McMaster team finds statin muscle pain is immune-driven
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- McMaster University researchers published a study in Science Advances identifying an immune response that explains statin-related muscle pain, weakness, and exercise intolerance in some patients.
- An estimated 7 to 29 percent of statin users experience muscle-related symptoms, and the new mechanism challenges earlier ideas about the origins of these side effects, said senior author Jonathan Schertzer.
- The team found statins disrupt how muscle cells generate energy, which triggers an immune response inside the muscle cells and leads to tissue damage.
- In experiments with muscle cells and mouse models, blocking the immune response prevented much of the damage, suggesting the pathway is a viable drug target.
- The side-effect mechanism appears separate from the cholesterol-lowering mechanism, raising the possibility that future drugs could protect muscle without interfering with statins' cardiovascular benefits.
- The international collaboration involved researchers from CIRI in Lyon, the University of Melbourne, Murdoch Children's Research Institute, The Royal Children's Hospital, and York University, with funding from NSERC.
Why it matters: For the 7–29% of statin users who experience muscle symptoms—sometimes severe enough to discontinue therapy critical for preventing heart attacks and strokes—this research identifies a biological pathway functionally separate from statins' cholesterol-lowering mechanism. More research is needed, but the study provides multiple specific targets for medications that protect muscle without dulling statins' cardiovascular benefits.
